

Jakafi® (Ruxolitinib) Prior Authorization Form

Member Name: _____ Date of Birth: _____ Member ID#: _____

Drug Information

Pharmacy billing (NDC: _____) Start Date (or date of next dose): _____

Dose: _____ Regimen: _____

Billing Provider Information

Pharmacy NPI: _____ Pharmacy Name: _____

Pharmacy Phone: _____ Pharmacy Fax: _____

Prescriber Information

Prescriber NPI: _____ Prescriber Name: _____

Prescriber Phone: _____ Prescriber Fax: _____ Specialty: _____

Criteria**For Initial Authorization****1. Please indicate the diagnosis and information:** **Graft-Versus-Host Disease (GVHD)**

A. Is diagnosis acute or chronic GVHD? Yes ___ No ___

B. Has the member failed at least 1 prior systemic therapy? Yes ___ No ___

 Myelofibrosis (MF)

A. Will ruxolitinib be used for symptomatic lower-risk MF with no response or loss of response to peginterferon alfa-2a or hydroxyurea? Yes ___ No ___

B. Will ruxolitinib be used for intermediate to high-risk MF? Yes ___ No ___

 Polycythemia Vera

A. Has member had an inadequate response or loss of response to hydroxyurea or peginterferon alfa-2a therapy? Yes ___ No ___

 If diagnosis is not listed above, please indicate diagnosis: _____

Additional Information: _____

For Continued Authorization:

1. Date of last dose: _____

2. Does member have any evidence of progressive disease while on ruxolitinib? Yes ___ No ___

3. Has the member experienced adverse drug reactions related to ruxolitinib therapy? Yes ___ No ___

If yes, please specify adverse reactions: _____

Prescriber Signature: _____ **Date:** _____**I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.***Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.*

Fax completed prior authorization request form to **888-601-8461** or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at **AetnaBetterHealth.com/Oklahoma**.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.